Friday briefing: Trump's Iran decision; National Guard; Dodger Stadium; listeria outbreak; ‘Jaws' 50th anniversary; and more
President Donald Trump will wait as much as two weeks to decide on striking Iran.
An appeals court allowed Trump to keep the National Guard in Los Angeles.
A man was accused of knocking on the Memphis mayor's door with a Taser.
Three people died in a listeria outbreak linked to packaged meals.
Plastic bag fees and bans help limit coastal litter, a new study found.
Archaeologists spent three months piecing together a huge Roman 'puzzle.'
'Jaws' was released 50 years ago today.
And now … hot where you are? Here are five things that may make you feel worse during extreme heat.
Want to catch up quickly with 'The 7' every morning? Download The Post's app and turn on alert notifications for The 7 or sign up for the newsletter.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Iranians saw America as better friend than Russia before war: Official
(NewsNation) — Iran's Health Ministry spokesman told NewsNation that Iranians viewed America as a better friend than Russia before President Donald Trump backed Israel's attacks. 'There was no perception about America prior to this. Some didn't like America, some had no opinion, and some considered America a better friend than Russia,' spokesman Hossein Kermanpour in an interview with NewsNation. A week into their war, Israel and Iran exchanged more strikes Friday as new diplomatic efforts led by the Europeans took place in Geneva. Kermanpour said Iranians were 'very surprised' by Trump and European support for the Israeli operation, adding that it confirmed suspicions that 'America is not to be trusted.' He said the strikes came 'in the midst of fruitful negotiations.' Iran nuclear weapons claims: What we know and what we don't However, he said that Iranians do not support U.S. involvement in the conflict with Israel following the recent strikes. Iran's Health Ministry reported more than 3,000 people injured in Israeli strikes, with 90% being civilians, and about 400 killed, according to Kermanpour. Kermanpour said about 2,000 of the injured have been treated and discharged. The casualties include a 2-month-old baby who was killed and a 4-year-old boy among the wounded, making them the youngest victims and injured, respectively. The Health Ministry spokesman said the attacks occurred 'while the people were sleeping' and targeted 'more than ten provinces of the country, including Tehran,' killing what he described as 'a significant number of civilians and military,' calling them 'martyrs.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
44 minutes ago
- Yahoo
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL. 'The amylin receptor is rapidly gaining clinical validation as a key target in obesity, driven by encouraging data from injectable peptide programs. We believe ACCG-2671 is well-positioned and differentiated as an oral small molecule frontrunner that is expected to enter clinical development by the end of 2025,' said Raymond Stevens, Ph.D., Founder and CEO of Structure Therapeutics. 'The preclinical data being presented at ADA include the robust weight-loss effects of ACCG-2671 alone and in combination with a GLP-1 receptor agonist underscoring ACCG-2671's potential as a future small molecule backbone treatment for obesity. In addition, we will present data demonstrating the neuroprotective effects of GLP-1 receptor agonism in preclinical models of Parkinson's disease, reinforcing the broad role of the GLP-1 receptor across different diseases.' Presentation Details: Title: Novel Oral Small Molecule ACCG-2671: A Dual Amylin and Calcitonin Receptor Agonist Development Candidate for Obesity TherapyPoster #: 2184-LBSession: Late Breaking Poster SessionDate: Sunday, June 22Time: 12:30 p.m. – 1:30 p.m. CT Summary: ACCG-2671 demonstrated high binding affinity and balanced potency in human calcitonin receptor (CTR) and amylin receptor (AMY3R) functional assays. In diet-induced obese rats, oral administration of ACCG-2671 resulted in significant, dose-dependent body weight reductions. Combination therapy with semaglutide (both as add-on and concurrent treatment) resulted in superior weight loss compared to monotherapy. Title: Oral Small Molecule GLP-1 Receptor Agonist Demonstrates Beneficial Effects in Parkinson's Disease–Like Model Using Humanized GLP-1R MicePoster #: 1985-LBSession: Late Breaking Poster SessionDate: Sunday, June 22Time: 12:30 p.m. – 1:30 p.m. CT Summary: In a Parkinson's disease mouse model, oral administration of GSBR-5595, a small molecule GLP-1 receptor agonist distinct from Structure Therapeutics' clinical asset aleniglipron (GSBR-1290), significantly improved motor coordination and movement in both the rotarod and open field tests. Additionally, histopathological analyses revealed a significant increase in dopaminergic neurons. These findings suggest this GLP-1 receptor agonist showed neuroprotective effects by mitigating motor deficits and preserving dopaminergic neurons, highlighting a potential benefit in Parkinson's disease. About Structure TherapeuticsStructure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit Forward Looking StatementsThis press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company's future plans and prospects; the belief that ACCG-2671 is well-positioned and differentiated as an oral small molecule frontrunner; the planned initiation of the ACCG-2671 Phase 1 study and the timing thereof; the belief that the oral small molecule approach gives Structure Therapeutics the opportunity to create more scalable, cost-effective treatments to meet the needs of patients with obesity and other related diseases, without compromising on efficacy or safety; the belief that Structure Therapeutics is well-positioned with one of the most robust oral small molecule metabolic franchises in the industry; and any expectations regarding the safety, efficacy or tolerability of ACCG-2671and other candidates under development. In addition, when or if used in this press release, the words and phrases 'anticipated,' 'expect,' 'on track,' 'plan,' 'potential,' 'to be,' and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company's forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to the results from earlier clinical studies not necessarily being predictive of future results, potential delays in the commencement, enrollment and completion of the Company's planned clinical studies, the Company's ability to advance ACCG-2671 and its other therapeutic candidates, obtain regulatory approval of and ultimately commercialize the Company's therapeutic candidates, competitive products or approaches limiting the commercial value of the Company's product candidates, the timing and results of preclinical and clinical studies, the Company's ability to fund development activities and achieve development goals, the Company's reliance on third parties, including clinical research organizations, manufacturers, suppliers and collaborators, over which it may not always have full control, the impact of any global pandemics, inflation, tariffs, changes in monetary and fiscal policy, supply chain issues, rising interest rates, future bank failures and other macroeconomic factors on the Company's business, its ability to protect its intellectual property and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Investors:Danielle KeatleyStructure Therapeutics Media:Dan Budwick1ABDan@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
"It's The Trifecta Of Bad": Dentists Are Sharing The Things They Would Avoid Doing To Their Teeth At All Costs
Brushing, flossing and visiting the dentist regularly — we all know the pillars of good dental hygiene. But knowing them and maintaining them are two different things. Nearly 50% of people above 30 have signs of gum disease and 26% of adults have untreated cavities, according to the Centers for Disease Control and Prevention. It's not uncommon to have issues with your teeth or gums, and dentists say certain lifestyle factors may be behind some of your oral health issues. In fact, common behaviors can negate the benefits of good oral hygiene — and you're probably guilty of some of them. Below, we spoke with dentists about the tooth-damaging habits and behaviors that they advise against and would never, ever do themselves: 1. They don't chew ice. 'The first thing that came to mind for me was chewing ice,' said Dr. Natalie Peterson, a clinical associate professor of dentistry at the University of Minnesota. 'A lot of people don't think about it, but they chew on the ice in their drink and they just don't think about the damage that it can do,' she said. Ice can break your teeth because not only is it hard, but it's cold, too, Peterson noted. It can be particularly damaging for people with fillings. 'The thought of chewing on ice just gives me shivers,' she said. 2. They don't bite their nails. According to Dr. Jennifer Soncini, a clinical associate professor of pediatric dentistry at Boston University, biting your nails can lead to dental issues. Plus, nail-biting is often a habit, which means your teeth have to deal with this action repeatedly. As you bite your nails, you wear down the enamel on the edges of your teeth, Soncini explained. Enamel plays many important roles — it helps protect your teeth from cavities, erosion, infection and sensitivity to cold, hot or sweet foods. 3. They don't open bags or bottles with their teeth. Related: Women Are Revealing How Their Lives Have Been Affected By President Trump's Policies, And They're Not Holding Back ANYTHING Using your teeth to open up a bag of chips or bottle of water may seem harmless, but dentists say it's not. 'Teeth are strong and very durable, but they are not meant to open bottle tops, tear apart packages or chew on hard objects,' Dr. Jarrett Manning, a comprehensive cosmetic and implant dentist and owner of JLM Dental Studios in Georgia, told HuffPost via email. It puts unnecessary stress on your teeth. 'Utilizing your teeth in this manner can lead to pain, broken or cracked teeth, root canals, or even teeth that need extracting,' Manning added. 4. They avoid eating gummy candy. Sticky candies like gummy worms, gummy bears and peach rings are all items that dentists steer clear of. Why? They can get stuck in the grooves of your teeth and between your teeth, which can cause cavities, Soncini said. They can also pop out fillings. Beyond gummy candy, Peterson said she specifically avoids sour gummies. 'I kind of think of these as the trifecta of bad. They're sticky, they're super sugary and they're really acidic — that's why they taste sour,' Peterson said. 5. They don't consume excessive amounts of alcohol. Related: 25 Eye-Opening Confessions From A Trauma Therapist That Changed The Way I Think About Mental Health It's well known that drinking too much alcohol is not good for your liver health, your cancer risk or your sleep quality. Manning said excessive alcohol consumption is bad for your teeth, too. 'Alcohol leads to dry mouth and decrease saliva production, and because saliva's role is to help cleanse the mouth, protect teeth and neutralize acids, a decrease in saliva can increase your risk of getting cavities,' Manning said. 6. They don't use a toothbrush with too-hard bristles. Peterson said she recommends toothbrushes with soft bristles for several reasons. Hard- and medium-bristle toothbrushes 'can be really abrasive to your gums, so they can cause more recession, and it's hard to fix recession once it's happened,' she explained. Also, toothbrushes with hard or medium bristles can be abrasive to your teeth in general, she said. 7. They don't smoke. 'I would never smoke or use tobacco,' Manning said. 'Not only can smoking lead to serious health issues, it can cause severe oral health issues, tooth discoloration and in extreme cases, oral cancer.' Smoking is a hard habit to quit, but there are resources available to help you achieve this goal. If you don't smoke, don't start for the sake of your oral health and beyond. 8. They don't skip out on their daily dental hygiene. This will likely not be surprising, but dentists say skipping brushing and flossing is a major no-no. 'Flossing daily along with brushing is the key to fighting gum disease,' Manning said. Additionally, Soncini said it's extra important to brush your teeth at night. 'Never ever, ever, ever go to sleep without brushing your teeth,' Soncini explained. 'You can spend a whole day without brushing, but if you don't brush before you go to bed, that is the worst you can do to your mouth.' Going to bed with a clean mouth can keep bacteria from growing overnight, Soncini said. 9. They don't miss dentist appointments. 'I also would never ignore my regular dental checkups,' Manning said. 'Routine dental checkups are crucial for maintaining oral health and catching dental issues early.' In terms of how often you should visit your dentist for routine checkups, it depends on your personal dental history and other issues. 'Regular checkups for patients should be kind of tailored for each individual patient and their risk factors and their overall dental health,' Peterson said. 'Some people might only need to come in once a year, they might be pretty healthy; a lot of people, twice a year is a good idea; and some people that have risk factors or dental problems, they might need to come in three to four times a year,' Peterson continued. Talk to your dentist and dental hygienist to figure out what the best frequency is for article originally appeared on HuffPost. Also in Goodful: Therapists Are Revealing The Moments That Made Them Break Their "No Judgment" Rule, And I'm Honestly Speechless Also in Goodful: 19 "Garbage" Modern Trends People Refuse To Partake In Despite Their Popularity Also in Goodful: "This Has Taken Me Years And Years And YEARS To Figure Out": This Woman's Clever Way To Tell If Someone Is Your Real Friend Is Being Called The Most Accurate Thing Ever
